55076-60-3

Basic information

• Product Name: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-2-one
• Synonyms: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-2-one;(3AR,4R,5R,6aS)-2-Oxo-4-((E)-3-oxo-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-5-yl be;2H-Cyclopenta[b]furan-2-one, 5-(benzoyloxy)hexahydro-4-[(1E)-3-oxo-5-phenyl-1-penten-1-yl]-, (3aR,4R,5R,6aS)-;LT-BK(3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-2-one;(3AR,4R,5R,6aS)-2-Oxo-4-((E)-3-oxo-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-5-yl;(3AR,4R,5R,6aS)-2-Oxo-4-((E)-3-oxo-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-5-yl benzoate
• CAS NO: 55076-60-3
• Molecular Formula: C₂₅H₂₄O₅
• Molecular Weight: 404.46
• Mol File: 55076-60-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: 117-118 °C
• Boiling Point: 606.9 °C at 760 mmHg
• Flash Point: 263 °C
• Appearance: /
• Density: 1.25
• Vapor Pressure: 1.12E-14mmHg at 25°C
• Refractive Index: 1.604
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-2-one(55076-60-3)
• EPA Substance Registry System: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-2-one(55076-60-3)

Safety Data

• Hazardous Substances Data: 55076-60-3(Hazardous Substances Data)

Usage

General Description

The chemical (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-2-one is a complex organic compound with a molecular structure that includes a hexahydro-cyclopenta[b]furan-2-one ring system, a phenyl group, and a benzoyloxy group. It also contains a 3-oxo-5-phenyl-1-pentenyl side chain. This chemical compound may have potential applications in pharmaceuticals, agrochemicals, or material science, and further research may be needed to explore its potential properties and uses.

InChI:InChI=1/C25H24O5/c26-19(12-11-17-7-3-1-4-8-17)13-14-20-21-15-24(27)29-23(21)16-22(20)30-25(28)18-9-5-2-6-10-18/h1-10,13-14,20-23H,11-12,15-16H2/b14-13+/t20-,21-,22-,23+/m1/s1

Upstream product

• 41162-19-0 dimethyl(2-oxo-4-phenylbutyl)phosphonate 
• 39746-01-5 (1S,5R,6R,7R)-6-formyl-7-benzoyloxy-2-oxabicyclo[3.3.0]octan-3-one 
• 140-10-3 (E)-3-phenylacrylic acid 
• 103-25-3 3-phenylpropanoic acid methyl ester 
• 501-52-0 3-Phenylpropionic acid 
• 40601-45-4 diethyl (2-oxo-4-phenylbutyl)phosphonate 
• 2550-26-7 4-Phenyl-2-butanone 
• 31984-10-8 1-bromo-4-phenylbutan-2-one 
• 1174193-89-5 4-phenyl-1-(1-phenyl-1H-tetrazole-5-sulfonyl)butan-2-one 

Downstream Products

• 55444-68-3 (3aR,4R,5R,6aS)-4-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-2-oxo-hexahydro-2H-cyclopenta[b]furan-5-yl benzoate 
• 41639-74-1 (3aR,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(1E,3S)-5-phenyl-3-hydroxy-(1E)-pentenyl]-2H-cyclopentane [β] furan-2-one 
• 69610-63-5 (3aR,4R,5R,6aS)-hexahydro-4-((3S,E)-5-phenyl-3-(tetrahydro-2H-pyran-2-yloxy)pent-1-enyl)-5-(tetrahydro-2H-pyran-2-yloxy)cyclopenta[b]furan-2-one 
• 55516-35-3 benzoic acid (3aR,4R,5R,6aS)-4-((E)-(R)-3-hydroxy-5-phenyl-pent-1-enyl)-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 856240-62-5 (3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol 
• 155206-00-1 bimatoprost 

Relevant articles and documents

Preparation method of bemeprost drug intermediate

The invention relates to the technical field of synthesis of medical intermediates, in particular to a preparation method of a bemeprost drug intermediate, which comprises the following steps: by using a compound I as a raw material, reacting with a compound II under the action of alkali to obtain the bemeprost drug intermediate: (3aR, 4R, 5R, 6aS)-5-(benzoyloxy)-hexahydro-4-[(1E)-3oxo-5-phenyl-1-pentenyl]-2H-cyclopenta-[b]-furan-2-ketone. According to the preparation method, the raw materials are easy to obtain, the stereoselectivity is higher, the yield and the purity are higher, and industrial production of the bemeprost drug intermediate is easier.

Improved Process for the Production of Prostaglandins and Prostaglandin Analogs

The present invention relates to an improved process for the production of prostaglandins and prostaglandin analogs. In particular, this invention relates to the production of prostaglandins of the PGF2α-series, including latanoprost, travoprost, and bimatoprost, which are active pharmaceutical ingredients used for the reduction of elevated intraocular pressure in patients with glaucoma and ocular hypertension.

METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE

A method for preparing a prostaglandin derivative represented by the following general formula (I): (wherein Ph represents phenyl group, R1 represents a C1-7 alkyl group, a C1-7 alkenyl group, phenyl group, or benzyl group), which comprises the successive steps (1) to (8) described in the specification, or any one step or two or more successive steps selected from the group consisting of the steps (1) to (8). A method for efficiently, inexpensively and safely preparing prostaglandin derivatives, of which typical example is latanoprost, is provided.